{"id":8932,"date":"2020-05-07T15:59:04","date_gmt":"2020-05-07T13:59:04","guid":{"rendered":"https:\/\/www.resist-cluster.de\/?page_id=8932"},"modified":"2022-02-02T12:44:12","modified_gmt":"2022-02-02T11:44:12","slug":"dr-martin-empting","status":"publish","type":"page","link":"https:\/\/www.resist-cluster.de\/en\/about-us\/research-team-2\/dr-martin-empting\/","title":{"rendered":"Dr. Martin Empting"},"content":{"rendered":"

<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/a><\/span><\/div>

Dr. Martin Empting participates in RESIST research projects C3 and D3.<\/p>\n<\/div>

<\/div><\/div><\/div>

\n\n\n
<\/i><\/td>\nMy Research Interest in RESIST<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/h1><\/div>

Our research focus in RESIST is the identification and optimization of small molecular compounds that interfere with novel and un(der)exploited drug targets against bacterial (C3) as well as viral infections (D3). The longterm aim is to thereby contribute to new treatment options for chronic lung infections as well as for herpesviral disease. In particular, we want to open the door for combination therapies that either utilize an antibiotic backbone treatment (C3) or drugs acting at different stages of the viral life cycle (D3). Recently, we have contributed to the discovery of a first generation of small molecule inhibitors acting on LANA and a pK15-dependent signal transduction cascade. Over the course of the next 6 years we want to continue with the optimization and development of these inhibitors and other inhibitors and apply the experience gained in recent years to other herpesviruses.\u00a0<\/span><\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/path><\/svg><\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>

Dr. Empting about his scientific work<\/h1><\/div>